Staphylococcus aureus bacteremia: Epidemiology, pathophysiology, and management strategies

Clinical Infectious Diseases

Volumn 48, Issue SUPPL. 4, 2009, Pages

  Nabera, Christoph K ^a  

^a ELISABETH KRANKENHAUS ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CORTICOSTEROID; COTRIMOXAZOLE; LINEZOLID; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BIOFILM; CELLULITIS; CENTRAL VENOUS CATHETERIZATION; CONFERENCE PAPER; CORTICOSTEROID THERAPY; EPIDEMIC; EUROPE; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PATHOGENICITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SKIN ULCER; STAPHYLOCOCCAL BACTEREMIA; SURGICAL INFECTION; ARTICLE; BACTEREMIA; COMMUNICABLE DISEASE; CROSS INFECTION; ECONOMICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HEALTH CARE COSTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 65649147226     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598189     Document Type: Conference Paper

References (50)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
2. Shorr AF, Lodise T. Burden of methicillin-resistant Staphylococcus aureus on healthcare cost and resource utilization. ISMR Update 2006; 1:4-11.
3. EARSS management team. European Antimicrobial Resistance Surveillance System annual report 2006. Bilthoven, The Netherlands: National Institute for Public Health and the Environment, 2007.
4. Steinberg JP, Clark CC, Hackman BO. Nosocomial and communityacquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23:255-9.
5. Troidle L, Eisen T, Pacelli L, Finkelstein F. Complications associated with the development of bacteremia with Staphylococcus aureus. Hemodial Int 2007; 11:72-5.
6. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012-21.
7. Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005; 41:507-14.
8. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45(Suppl 3):S171-6.
9. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.
10. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50:59-69.
11. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 2006; 34:2588-95.
12. EARSS management team. European Antimicrobial Resistance Surveillance System database. Bilthoven, The Netherlands: National Institute for Public Health and the Environment, 2008.
13. Coombs GW, Pearson JC, O'Brien FG, Murray RJ, Grubb WB, Christianse KJ. Methicillin-resistant Staphylococcus aureus clones, Western Australia. Emerg Infect Dis 2006; 12:241-7.
14. Klevens RM, Morrison MA, Nadle J, et al. Invasivemethicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-71.
15. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 2007; 87:3-9.
16. Chini V, Petinaki E, Foka A, Paratiras S, Dimitracopoulos G, Spiliopoulou I. Spread of Staphylococcus aureus clinical isolates carrying Panton- Valentine leukocidin genes during a 3-year period in Greece. Clin Microbiol Infect 2006; 12:29-34.
17. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005; 41(Suppl 4):S269-72.
18. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-32.
19. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647-56.
20. Saiman L, O'Keefe M, Graham PL III, et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37:1313-9.
21. Lesse AJ, Mylotte JM. Clinical and molecular epidemiology of nursing home-associated Staphylococcus aureus bacteremia. Am J Infect Control 2006; 34:642-50.
22. Fowler VG Jr, Sanders LL, Kong LK, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with followup. Clin Infect Dis 1999; 28:106-14.
23. Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia: a prospective, multicenter study. Ann Intern Med 1993; 119:560-7.
24. Ruotsalainen E, Sammalkorpi K, Laine J, et al. Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients. BMC Infect Dis 2006; 6:137.
25. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
26. Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002; 78:385-92.
27. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001; 344:11-6.
28. Tacconelli E, Venkataraman L, De Girolami PC, DAgata EM. Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 2004; 53:474-9.
29. Carnicer-Pont D, Bailey KA, Mason BW, Walker AM, Evans MR, Salmon RL. Risk factors for hospital-acquired methicillin-resistant Staphylococcus aureus bacteraemia: a case-control study. Epidemiol Infect 2006; 134:1167-73.
30. Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J 2005; 35(Suppl 2):S17-24.
31. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066-72.
32. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillinresistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
33. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-35.
34. Whitby M, McLaws ML, Berry G. Risk of death from methicillinresistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001; 175:264-7.
35. Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005; 165:1756-61.
36. Reed SD, Friedman JY, Engemann JJ, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin- susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26:175-83.
37. Nissenson AR, Dylan ML, Griffiths RI, et al. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis 2005; 46:301-8.
38. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25:181-5.
39. Weidenmaier C, Kokai-Kun JF, Kristian SA, et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004; 10:243-5.
40. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000; 6:1275-7.
41. Otto M. Quorum-sensing control in staphylococci-a target for antimicrobial drug therapy? FEMS Microbiol Lett 2004; 241:135-41.
42. Haas PJ, de Haas CJ, Kleibeuker W, et al. N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol 2004; 173:5704-11.
43. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55: 77-104.
44. Wang ZQ, Orlikowsky T, Dudhane A, et al. Staphylococcal enterotoxin B-induced T-cell anergy is mediated by regulatory T cells. Immunology 1998; 94:331-9.
45. Proctor RA, Kahl B, von Eiff C, Vaudaux PE, Lew DP, Peters G. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis 1998; 27(Suppl 1):S68-74.
46. Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat Res 2005; 41-7.
47. Jansen WT, Beitsma MM, Koeman CJ, Van Wamel WJ, Verhoef J, Fluit AC. Novel mobile variants of staphylococcal cassette chromosome mec in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 2072-8.
48. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12(Suppl 1):16-23.
49. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15.
50. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005; 330:102-4.5